8-K: Verano Holdings Reports Strong Q2 2026 Results

Verano Holdings Corp. announced robust second quarter 2026 financial results, featuring $218 million in revenue and improved operational cash flow, marking the third consecutive quarter of revenue gains.

Summary

• Verano Holdings Corp. reported second quarter 2026 revenue of $218 million, an increase of 5% from the previous quarter and 8% year-over-year.
• Gross profit was $100 million, representing 46% of revenue.
• Selling, General, and Administrative (SG&A) expenses were $92 million, or 42% of revenue.
• The company reported a net loss of $13 million for the quarter.
• Adjusted EBITDA was $51 million, or 24% of revenue.
• Net cash provided by operating activities was $31 million.
• Capital expenditures for the quarter were $12 million.
• The company tightened its 2026 capital expenditure guidance to $40 million $50 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with revenue growth and improved cash flow, though net losses persist. The strategic moves and industry context suggest a company navigating challenges effectively.

Positives

• Revenue increased to $218 million, up 5% sequentially and 8% year-over-year, marking the third consecutive quarter of revenue growth.
• Adjusted EBITDA of $51 million indicates strong operational profitability before certain expenses.
• Net cash provided by operating activities was $31 million, a significant improvement.
• The company repurchased $2 million of its stock.
• Expanded retail footprint with the opening of a new dispensary in Florida, bringing the total to 163 nationwide.
• The medical cannabis rescheduling announcement from Schedule I to Schedule III is a significant positive industry development.

Negatives

• The company reported a net loss of $13 million for the second quarter of 2026.
• Gross profit margin decreased to 46% from 48% in the prior quarter and 56% in the prior year quarter.
• SG&A expenses as a percentage of revenue increased to 42% from 41% in the prior quarter.

Risks

• The company's financial statements are prepared in accordance with U.S. GAAP, but the report also relies on non-U.S. GAAP measures like Adjusted EBITDA, which may not be comparable to other companies.
• Forward-looking statements are subject to assumptions, known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.
• The cannabis industry faces regulatory uncertainties and evolving legal landscapes.

Future Outlook

The company expects to accelerate business momentum in what may be a pivotal year, with additional retail expansion and new product innovation planned for the remainder of the year. 2026 capital expenditure guidance has been tightened to a range of $40 million to $50 million.

Management Comments

• "We are thrilled to report strong second quarter results highlighted by organic growth, improved operational cash flow, and our third consecutive quarter of revenue gains that also outperformed the prior year period."
• "During the quarter, we also executed key strategic pillars to deepen our engagement in the U.S. capital markets and U.S. exchange opportunities, including repurchasing $2 million of Company stock and completing a 1-for-5 reverse stock split, while leveraging the ongoing strength of our retail operations and product portfolio."
• "As we continue fortifying the balance sheet, with additional retail expansion and new product innovation planned for the remainder of the year, we are in a strong position to accelerate further business momentum in what may be a pivotal year for Verano and the industry at large."

Industry Context

StockSavvy.ai notes that Verano's results are being released amidst significant industry developments, including the potential rescheduling of cannabis from Schedule I to Schedule III by the U.S. government. This rescheduling could have profound implications for the industry's regulatory landscape and financial operations.

Comparison to Industry Standards

• Verano's revenue growth of 8% year-over-year in Q2 2026 is a positive indicator in a competitive multi-state operator (MSO) market.
• The Adjusted EBITDA margin of 24% is a key metric for MSOs; while strong, it needs to be compared against peers like Curaleaf, Trulieve, and Green Thumb Industries for a comprehensive view.
• The net loss of $13 million, despite revenue growth, highlights the ongoing profitability challenges faced by many in the cannabis sector, which often struggle to achieve consistent GAAP profitability due to high operating costs and regulatory burdens.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and improved cash flow, offset by continued net losses and the impact of a 1-for-5 reverse stock split.
• Employees: Continued operational expansion may lead to job creation.
• Customers: Access to a wider retail footprint and potentially new product innovations.
• Creditors: Improved operational cash flow may enhance the company's ability to service debt.

Next Steps

• Continue retail expansion and new product innovation.
• Fortify the balance sheet.
• Accelerate business momentum.
• Monitor developments regarding medical cannabis rescheduling.
• Prepare for the launch of Virginia's adult-use cannabis market in July 2027.

Key Dates

Recommendation

The company shows positive revenue growth and improved operational cash flow, which are encouraging signs. However, the persistent net loss and the impact of a reverse stock split warrant a cautious approach. While the industry outlook is improving with potential rescheduling, further evidence of consistent GAAP profitability is needed for a stronger recommendation.

Keywords

cannabis, revenue, Adjusted EBITDA, financial results, retail, operations, Florida, Nevada